Organon, Samsung Bioepis launch copycat for arthritis drug Humira at 85% discount

Argentina Noticias Noticias

Organon, Samsung Bioepis launch copycat for arthritis drug Humira at 85% discount
Argentina Últimas Noticias,Argentina Titulares
  • 📰 Reuters
  • ⏱ Reading Time:
  • 29 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 15%
  • Publisher: 97%

Drugmaker partners Organon and Samsung Bioepis said on Saturday that they had launched a far cheaper copycat version of AbbVie’s blockbuster arthritis drug Humira, while two other drugmakers entered the market with much more modest discounts to the branded medicine's list price.

July 1 - Drugmaker partners Organon and Samsung Bioepis said on Saturday that they had launched a far cheaper copycat version of AbbVie’s

The copycat drug called Hadlima will be listed at $1,038 per month, representing an 85% discount of Humira’s current $6,922 monthly price, the companies said. Germany-based Boehringer Ingelheim later said it released its rival version of Humira, Cyltezo, at a 5% to 7% price cut from the list price of the branded medicine.

Organon and Samsung Bioepis did not say if they had struck deals with pharmacy benefit managers , which negotiate insurance coverage on behalf of large employers and health insurance plans, to secure reimbursement of Hadlima for patients.

Hemos resumido esta noticia para que puedas leerla rápidamente. Si estás interesado en la noticia, puedes leer el texto completo aquí. Leer más:

Reuters /  🏆 2. in US

Argentina Últimas Noticias, Argentina Titulares

Similar News:También puedes leer noticias similares a ésta que hemos recopilado de otras fuentes de noticias.

Organon, Samsung Bioepis launch copycat for arthritis drug Humira at 85% discountOrganon, Samsung Bioepis launch copycat for arthritis drug Humira at 85% discountDrugmaker partners Organon and Samsung Bioepis said on Saturday that they had launched a far cheaper copycat version of AbbVie’s blockbuster arthritis drug Humira, while another drugmaker entered the market with a much more modest discount to the branded medicine's list price.
Leer más »

Cheaper competition for Humira is hitting the market, but savings will depend on your insuranceCheaper competition for Humira is hitting the market, but savings will depend on your insurancePatients who take the autoimmune disease treatment Humira may see some price relief when several lower-cost, biosimilar versions of the AbbVie drug reach the U.S. market in July.
Leer más »

Cheaper competition for Humira is hitting the market, but savings will depend on your insuranceCheaper competition for Humira is hitting the market, but savings will depend on your insurancePatients who take the autoimmune disease treatment Humira may see some price relief when several lower-cost, biosimilar versions of the AbbVie drug reach the U.S. market in July.
Leer más »

For AbbVie’s blockbuster Humira, cheaper competitors pose surprisingly little threat, analysts sayFor AbbVie’s blockbuster Humira, cheaper competitors pose surprisingly little threat, analysts sayLower-price biosimilar competition for top-selling drug launching this weekend.
Leer más »

Humira, the world’s top-selling drug, faces an upcoming test from low cost alternativesHumira, the world’s top-selling drug, faces an upcoming test from low cost alternativesNew Humira alternatives will be available in July. This could make the drug that now costs nearly $80,000 per year more affordable.
Leer más »

Will lower-cost Humira pharmaceutical options soon be available to patients?Will lower-cost Humira pharmaceutical options soon be available to patients?Seven new alternatives to the high-cost Humira drug will be available in July. Some will be offered at significantly lower prices, but will patients see big...
Leer más »



Render Time: 2025-03-20 19:49:07